Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 5/20 | 0.57 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.57 |
| ▸ | DHFR | P00374 | 6/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30413525 | 1.00 | SCN2A (0.57) | SCN2AKCNK2DHFRFGFR1SRC | |
| SCHEMBL15914195 | 0.86 | SCN2A (0.49) | SCN2AKCNK2DHFRFGFR1SRC | |
| SCHEMBL7279421 | 0.84 | DHFR (0.54) | SCN2AKCNK2DHFRFGFR1SRC | |
| SCHEMBL6049521 | 0.80 | SCN2A (0.54) | SCN2AKCNK2DHFRFGFR1SRC | |
| SCHEMBL6049564 | 0.80 | SCN2A (0.54) | SCN2AKCNK2DHFRFGFR1SRC | |
| SCHEMBL4196232 | 0.79 | DHFR (0.61) | DHFRFGFR1SRCSCN10AADORA2A | |
| SCHEMBL7279386 | 0.79 | DHFR (0.53) | SCN2AKCNK2DHFRFGFR1SRC | |
| SCHEMBL1388588 | 0.79 | DHFR (0.59) | DHFRFGFR1SRCADORA2AADORA1 | |
| SCHEMBL6049508 | 0.77 | DHFR (0.55) | SCN2AKCNK2DHFRFGFR1SRC | |
| SCHEMBL7280072 | 0.77 | DHFR (0.50) | SCN2AKCNK2DHFRFGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906919-B2 | Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers | OZTEO PTY LTD (AU) | 2014-12-09 | — | — | US | claimed |
| US-20120172363-A1 | Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers | Ozleo Pty Ltd (AU) | 2012-07-05 | — | — | US | claimed |
| EP-2453893-A1 | TREATMENT OF NON-NEURONAL AND NON-MYOCARDIAL CELL, TISSUE AND ORGAN DAMAGE AND ASSOCIATED PAIN WITH PERSISTENT SODIUM CURRENT BLOCKERS | Ozteo Pty Ltd (AU) | 2012-05-23 | — | — | EP | claimed |
| WO-2011003129-A1 | TREATMENT OF NON-NEURONAL AND NON-MYOCARDIAL CELL, TISSUE AND ORGAN DAMAGE AND ASSOCIATED PAIN WITH PERSISTENT SODIUM CURRENT BLOCKERS | OZTEO PTY LTD (AU) | 2011-01-13 | — | — | WO | claimed |
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | claimed |
| EP-1586321-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2005-10-19 | — | — | EP | claimed |
| US-20040229873-A1 | Treatment of neurodegenerative conditions | BTG INTERNATIONAL LIMITED (GB) | 2004-11-18 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| US-5587380-A | ANTIISCHEMIC AGENTS | GLAXO WELLCOME INC. (US) | 1996-12-24 | — | — | US | claimed |
| CN-1052306-A | Compounds having pharmacological activity on the central nervous system | WELLCOME FOUND (GB) | 1991-06-19 | — | — | CN | claimed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | claimed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| EP-0679645-A1 | Pharmacologically active CNS pyridmidin compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-11-02 | — | — | EP | disclosed |
| US-5136080-A | Intermediates for glutamate inhibitors | BURROUGHS WELLCOME CO. (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0459819-A2 | Pharmacologically active CNS compound | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-04 | — | — | EP | disclosed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172363-A1 | Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers | TNNI3, TNNC1, HCN4 | SCN2A 30/4885KCNK2 213/4885DHFR 3998/4885 |
| US-20040229873-A1 | Treatment of neurodegenerative conditions | CHRM2, CHRNA3, CHRNA2 | SCN2A 63/4885KCNK2 136/4885DHFR 3298/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | SCN2A 1556/4885KCNK2 2958/4885DHFR 1871/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | SCN2A 3093/4885KCNK2 2889/4885DHFR 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.